Yale study validates enfortumab vedotin as therapy for aggressive bladder cancer

DDR gene mutations associated with complete response to chemo in bladder cancer

Tumors with alterations in any of three specific genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.

August 02, 2024

Vol.50 No.31

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

Drugs & Targets

FDA approves Anktiva for non-muscle-invasive bladder cancer

FDA has approved ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

April 26, 2024

Vol.50 No.17

In Brief

Roy Herbst elected to Friends board of directors

Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.

January 12, 2024

Vol.50 No.02

In Brief

ACCC establishes bladder cancer care resource

The Association of Community Cancer Centers has established a new e-course, Implementing Shared Decision-Making in Bladder Cancer Care, as part of its resources for cancer care centers to access evidence-based health literacy principles and shared decision-making strategies to reduce disparities in bladder cancer care.

January 12, 2024

Vol.50 No.02

Yale study validates enfortumab vedotin as therapy for aggressive bladder cancer

YOU MAY BE INTERESTED IN

DDR gene mutations associated with complete response to chemo in bladder cancer

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

FDA approves Anktiva for non-muscle-invasive bladder cancer

Roy Herbst elected to Friends board of directors

ACCC establishes bladder cancer care resource

Renew today!

Subscriber content

Login